Company intelligence / Profile preview

Regencell Bioscience

Ownership: Private
Development stage: Commercial

Overview

Regencell Bioscience develops proprietary TCM-based treatments for neurocognitive disorders such as ADHD and ASD. The company aims to be a global leader in this space but has not publicly disclosed detailed clinical trial results or regulatory milestones as of May 2025.

Therapeutic areas: Psychiatry
Modalities: Traditional Chinese Medicine (TCM) formulations
Industry: Biotech

Drug pipeline

1 asset

RGC-COV19

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Regencell Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regencell Bioscience.

Explore the full profile